Even In This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value

Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent quarters, this biotech still generates bucketloads of cash, and the recent acquisition of a breakthrough cancer therapy could turn the tide. The average stock in the benchmark S&P 500 index trades at a price around 25 times the amount of profit earned over the past year. That makes Gilead Sciences' single-digit earnings multiple seem downright irresistible to bargain shoppers.Image source: Getty Images.Continue reading

Topics:  inc nasdaq gild    gilead sciences   images   sciences   market   stock   
BING NEWS:
  • Gilead Q1 Earnings Preview: Most Gains Wiped Out
    Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Check out whether GILD stock is a good buy ahead of Q1 earnings.
    04/23/2024 - 2:00 am | View Link
  • What the Options Market Tells Us About Gilead Sciences
    Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $75.0 for Gilead Sciences over the last 3 months.
    04/18/2024 - 6:16 am | View Link
  • Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns
    In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Gilead Sciences (GILD – Research Report), with ...
    04/17/2024 - 11:06 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News